Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer
ACS Medicinal Chemistry Letters · 09.02.2023 · 14 (2) · 131-132
DOI: 10.1021/acsmedchemlett.2c00543 ↗Kurz gefasst
Editorial in der Zeitschrift ACS Medicinal Chemistry Letters, online erschienen am 23.01.2023. Verfasst von Robert B Kargbo. Beteiligte Einrichtung: Usona Institute, Fitchburg, Wisconsin 53711-5300, United States. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
ALDH1A3 is an important member of 19 aldehyde dehydrogenases, which metabolize reactive aldehydes to their corresponding carboxylic acids, detoxify endogenous and exogenous aldehydes, and are also involved in the biosynthesis of retinoic acid. In addition, ALDH1A3 plays important physiological and toxicological roles in different pathologies, including type II diabetes, obesity, cancer, pulmonary arterial hypertension, and neointimal hyperplasia. Consequently, inhibition of ALDH1A3 may offer new therapeutic options for patients with cancer, obesity, diabetes, and cardiovascular disorder.
Autor:innen und Institutionen
- Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
ORCID-Profile: Robert B Kargbo
Zitieren
APA
Kargbo, R. B. (2023). Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer. ACS Medicinal Chemistry Letters, 14(2), 131-132. https://doi.org/10.1021/acsmedchemlett.2c00543
Vancouver
Kargbo RB. Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer. ACS Medicinal Chemistry Letters. 2023;14(2):131-132. doi:10.1021/acsmedchemlett.2c00543
BibTeX
@article{Kargbo2023,
author = {Kargbo, Robert B},
title = {Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer},
journal = {ACS Medicinal Chemistry Letters},
year = {2023},
volume = {14},
number = {2},
pages = {131--132},
doi = {10.1021/acsmedchemlett.2c00543}
}
EUVIMED